OPENAI DEPLOYS AI AS A BIOWEAPON SHIELD — NEW PROGRAM PUTS GPT-ROSALIND IN THE HANDS OF GOVERNMENT LABS OpenAI launched a new biodefense initiative called Rosalind Biodefense, extending trusted access to its GPT-Rosalind model to vetted researchers, U.S. government partners, and allied public health organizations working to counter biological threats. The model builds on GPT-5.5 with enhanced drug discovery capability and runs long quantitative biology analyses using 31 percent fewer computational resources than its predecessors. OpenAI calls its strategy defensive acceleration. The argument is simple: frontier AI should reach the people guarding against outbreaks faster than it reaches anyone else. The company briefed the White House and several federal agencies during the rollout. Early access partners include Johns Hopkins Applied Physics Laboratory and the Coalition for Epidemic Preparedness Innovations. Approved use cases include epidemiological modeling, outbreak early warning systems, diagnostics development, and medical countermeasure research. The announcement arrives as lawmakers and regulators are still debating what rules, if any, should govern AI access to sensitive biological research. OpenAI is not waiting for those rules to be written. It is establishing norms by acting. The dual use tension here is real and acknowledged by critics. A model powerful enough to model pathogen behavior for defensive purposes is also a model that could be misused. OpenAI says access controls and vetting processes address that risk. Whether those controls are sufficient is a question regulators will be asking for years. Keywords: OpenAI biodefense, GPT-Rosalind, AI biological threats, OpenAI government program